FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma ascopost.com
Finance, IT & News
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma ascopost.com
FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma Oncology Nursing News
BWX Technologies gets its first investment-grade rating, with a stable outlook Stock Titan
Fitch revises Kansas rating outlook to positive Bond Buyer
S&P upgrades Skeena Resources outlook on mine progress Investing.com